Alkeon Capital Management
RXRX icon

Alkeon Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Alkeon Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-548,455
Closed -$12.6M – 173
2021
Q3 		$12.6M Sell
548,455
-1,545
-0.3% -$43.8K 0.02% 148
2021
Q2 		$20.1M Buy
+550,000
New +$16.3M 0.03% 143

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Alkeon Capital Management's RXRX Position: Q4 2021 in Review

Alkeon Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2021, closing a stake of 548,455 shares — an estimated $12.6M sold.

Alkeon Capital Management first reported a position in RXRX in Q2 2021 and held it in 2 quarters. The position peaked at $20.1M in Q2 2021. 126 funds tracked by Wall St. Rank hold RXRX as of Q4 2021.

  • Alkeon Capital Management reported no remaining Recursion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Alkeon Capital Management sold 548,455 Recursion Pharmaceuticals shares in Q4 2021, an estimated $12.6M.
  • Alkeon Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Alkeon Capital Management's Recursion Pharmaceuticals position peaked at $20.1M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2021.

Based on Alkeon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.